Secretory leukocyte protease inhibitor influences periarticular joint inflammation in B. burgdorferi-infected mice

  1. Section of Infectious Diseases, Department of Internal Medicine, School of Medicine, Yale University, New Haven, United States
  2. Institute of Insect Sciences, College of Agriculture and Biotechnology, Zhejiang University, Hangzhou, China
  3. Department of Pathology, School of Medicine, Yale University, New Haven, United States
  4. Section of Rheumatology, Allergy and Immunology, Department of Internal Medicine, School of Medicine, Yale University, New Haven, United States
  5. Department of Immunobiology, Yale School of Medicine, New Haven, United States
  6. Department of Pharmacology, Yale School of Medicine, New Haven, United States
  7. Divisions of Immunology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan

Peer review process

Not revised: This Reviewed Preprint includes the authors’ original preprint (without revision), an eLife assessment, public reviews, and a provisional response from the authors.

Read more about eLife’s peer review process.

Editors

  • Reviewing Editor
    Huihui Li
    Icahn School of Medicine at Mount Sinai, New York, United States of America
  • Senior Editor
    Dominique Soldati-Favre
    University of Geneva, Geneva, Switzerland

Reviewer #1 (Public review):

Summary:

This study demonstrates the significant role of secretory leukocyte protease inhibitor (SLPI) in regulating B. burgdorferi-induced periarticular inflammation in mice. They found that SLPI-deficient mice showed significantly higher B. burgdorferi infection burden in ankle joints compared to wild-type controls. This increased infection was accompanied by infiltration of neutrophils and macrophages in periarticular tissues, suggesting SLPI's role in immune regulation. The authors strengthened their findings by demonstrating a direct interaction between SLPI and B. burgdorferi through BASEHIT library screening and FACS analysis. Further investigation of SLPI as a target could lead to valuable clinical applications.

The conclusions of this paper are mostly well supported by data, but two aspects need attention:

(1) Cytokine Analysis:
The serum cytokine/chemokine profile analysis appears without TNF-alpha data. Given TNF-alpha's established role in inflammatory responses, comparing its levels between wild-type and infected B. burgdorferi conditions would provide valuable insight into the inflammatory mechanism.
(2) Sample Size Concerns:
While the authors note limitations in obtaining Lyme disease patient samples, the control group is notably smaller than the patient group. This imbalance should either be addressed by including additional healthy controls or explicitly justified in the methodology section.

Reviewer #2 (Public review):

Summary:

This manuscript by Yu and coworkers investigates the potential role of Secretory leukocyte protease inhibitor (SLPI) in Lyme arthritis. They show that, after needle inoculation of the Lyme disease (LD) agent, B. burgdorferi, compared to wild type mice, a SLPI-deficient mouse suffers elevated bacterial burden, joint swelling and inflammation, pro-inflammatory cytokines in the joint, and levels of serum neutrophil elastase (NE). They suggest that SLPI levels of Lyme disease patients are diminished relative to healthy controls. Finally, they find that SLPI may interact directly the B. burgdorferi.

Strengths:

Many of these observations are interesting and the use of SLPI-deficient mice is useful (and has not previously been done).

Weaknesses:

(a) The known role of SLPI in dampening inflammation and inflammatory damage by inhibition of NE makes the enhanced inflammation in the joint of B. burgdorferi-infected mice a predicted result; (b) The potential contribution of the greater bacterial burden to the enhanced inflammation is not addressed; (c) The relationship of SLPI binding by B. burgdorferi to the enhanced disease of SLPI-deficient mice is not clear; and (d) Several methodological aspects of the study are unclear.

Reviewer #3 (Public review):

Summary:

The authors investigated the role of secretory leukocyte protease inhibitors (SLPI) in developing Lyme disease in mice infected with Borrelia burgdorferi. Using a combination of histological, gene expression, and flow cytometry analyses, they demonstrated significantly higher bacterial burden and elevated neutrophil and macrophage infiltration in SLPI-deficient mouse ankle joints. Furthermore, they also showed direct interaction of SLPI with B. burgdorferi, which likely depletes the local environment of SLPI and causes excessive protease activity. These results overall suggest ankle tissue inflammation in B. burgdorferi-infected mice is driven by unchecked protease activity.

Strengths:

Utilizing a comprehensive suite of techniques, this is the first study showing the importance of anti-protease-protease balance in the development of periarticular joint inflammation in Lyme disease.

Weaknesses:

Due to the limited sample availability, the authors investigated the serum level of SLPI in both in Lyme arthritis patients and patients with earlier disease manifestations.

Author response:

Public Reviews:

Reviewer #1 (Public review):

Summary:

This study demonstrates the significant role of secretory leukocyte protease inhibitor (SLPI) in regulating B. burgdorferi-induced periarticular inflammation in mice. They found that SLPI-deficient mice showed significantly higher B. burgdorferi infection burden in ankle joints compared to wild-type controls. This increased infection was accompanied by infiltration of neutrophils and macrophages in periarticular tissues, suggesting SLPI's role in immune regulation. The authors strengthened their findings by demonstrating a direct interaction between SLPI and B. burgdorferi through BASEHIT library screening and FACS analysis. Further investigation of SLPI as a target could lead to valuable clinical applications.

The conclusions of this paper are mostly well supported by data, but two aspects need attention:

(1) Cytokine Analysis:

The serum cytokine/chemokine profile analysis appears without TNF-alpha data. Given TNF-alpha's established role in inflammatory responses, comparing its levels between wild-type and infected B. burgdorferi conditions would provide valuable insight into the inflammatory mechanism.

(2) Sample Size Concerns:

While the authors note limitations in obtaining Lyme disease patient samples, the control group is notably smaller than the patient group. This imbalance should either be addressed by including additional healthy controls or explicitly justified in the methodology section.

We thank the reviewer for the careful review and positive comments.

(1) We did look into the level of TNF-alpha in both WT and SLPI-/- mice with and without B. burgdorferi infection. At serum level, using ELISA, we did not observe any significant difference between all four groups. At gene expression level, using RT-qPCR on the tibiotarsal tissue, we also did not observe any significant differences. Our RT-qPCR result is consistent with the previous microarray study using the whole murine joint tissue (DOI: 10.4049/jimmunol.177.11.7930). The microarray study did not show significant changes in TNF-alpha level in C57BL/6 mice following B. burgdorferi infection. The above data suggest that TNF-alpha does not involve in SLPI-regulated immune responses in the murine tibiotarsal tissue following B. burgdorferi infection. A brief discussion will be added, and the above data will be provided as a supplemental figure in the revised manuscript.

(2) We agree with the reviewer that the control group is smaller than the patient group. Among the archived samples that are available, the number of adult healthy controls are limited. It has been shown that the serum level of SLPI in healthy volunteers is in average about 40 ng/ml (DOI: 10.3389/fimmu.2019.00664 and 10.1097/00003246-200005000-00003). The median level in the healthy control in our data was 38.92 ng/ml, which is comparable to the previous results. A brief discussion will be added in the revised manuscript.

Reviewer #2 (Public review):

Summary:

This manuscript by Yu and coworkers investigates the potential role of Secretory leukocyte protease inhibitor (SLPI) in Lyme arthritis. They show that, after needle inoculation of the Lyme disease (LD) agent, B. burgdorferi, compared to wild type mice, a SLPI-deficient mouse suffers elevated bacterial burden, joint swelling and inflammation, pro-inflammatory cytokines in the joint, and levels of serum neutrophil elastase (NE). They suggest that SLPI levels of Lyme disease patients are diminished relative to healthy controls. Finally, they find that SLPI may interact directly the B. burgdorferi.

Strengths:

Many of these observations are interesting and the use of SLPI-deficient mice is useful (and has not previously been done).

We appreciate the reviewer’s careful reading and positive comments.

Weaknesses:

(a) The known role of SLPI in dampening inflammation and inflammatory damage by inhibition of NE makes the enhanced inflammation in the joint of B. burgdorferi-infected mice a predicted result;

We agree that the observation of the elevated NE level and the enhanced inflammation is theoretically likely. Indeed, that was the hypothesis that we explored, and often what is theoretically possible does not turn out to occur. In addition, despite the known contribution of neutrophils to the severity of murine Lyme arthritis, the importance of the neutrophil serine proteases and anti-protease has not been specifically studied, and neutrophils secrete many factors. Therefore, our data fill an important gap in the knowledge of murine Lyme arthritis development – and set the stage for the further exploration of this hypothesis in the genesis of human Lyme arthritis.

(b) The potential contribution of the greater bacterial burden to the enhanced inflammation is not addressed;

We agree with the reviewer’s viewpoint that the increased infection burden in the tibiotarsal tissue of the infected SLPI-/- mice could contribute to the enhanced inflammation. A brief discussion of this possibility will be added to the revised manuscript.

(c) The relationship of SLPI binding by B. burgdorferi to the enhanced disease of SLPI-deficient mice is not clear; and

We agree with the reviewer that we have not shown the importance of the SLPI-B. burgdorferi binding in the development of periarticular inflammation. It is an ongoing project in our lab to identify the SLPI binding partner in B. burgdorferi. Our hypothesis is that SLPI could bind and inhibit an unknown B. burgdorferi virulence factor that contributes to murine Lyme arthritis. We will include the above discussion in the revised manuscript.

(d) Several methodological aspects of the study are unclear.

We appreciate the critique and will modify the method session in greater detail in the revised manuscript.

Reviewer #3 (Public review):

Summary:

The authors investigated the role of secretory leukocyte protease inhibitors (SLPI) in developing Lyme disease in mice infected with Borrelia burgdorferi. Using a combination of histological, gene expression, and flow cytometry analyses, they demonstrated significantly higher bacterial burden and elevated neutrophil and macrophage infiltration in SLPI-deficient mouse ankle joints. Furthermore, they also showed direct interaction of SLPI with B. burgdorferi, which likely depletes the local environment of SLPI and causes excessive protease activity. These results overall suggest ankle tissue inflammation in B. burgdorferi-infected mice is driven by unchecked protease activity.

Strengths:

Utilizing a comprehensive suite of techniques, this is the first study showing the importance of anti-protease-protease balance in the development of periarticular joint inflammation in Lyme disease.

We greatly appreciate the reviewer’s careful reading and positive comments.

Weaknesses:

Due to the limited sample availability, the authors investigated the serum level of SLPI in both in Lyme arthritis patients and patients with earlier disease manifestations.

We agree with the reviewer that it would be ideal to have more samples from Lyme arthritis patients. However, among the available archived samples, samples from Lyme arthritis patients are limited. For the samples from patients with single EM, the symptom persisted into 3-4 month after diagnosis, the same timeframe when arthritis is developed. We will add the above discussion in the revised manuscript.

Recommendations for the authors:

Reviewer #1 (Recommendations for the authors):

(1) In Figure 2, for histological scoring, do they have similar n numbers?

In panel B, 20 infected WT mice and 19 infected SLPI-/- mice were examined. In panel D, 13 infected WT and SLPI-/- mice were examined. Without infection, WT and SLPI-/- mice do not develop spontaneous arthritis. Due to the slow breeding of the SLPI-/- mice, a small number of uninfected control animals were used.

(2) In Figure 3, for macrophage population analysis, maybe consider implementing Ly6G-negative gating strategy to prevent neutrophil contamination in macrophage population?

We appreciate reviewer’s suggestion. We will analyze the data using the Ly6G-negative gating strategy and provide the result in a supplemental figure. We will compare the results using the two gating strategies in the revised manuscript.

Reviewer #2 (Recommendations for the authors):

(1) The investigators should address the possibility that much of the enhanced inflammatory features of infected SLPI-deficient mice are simply due to the higher bacterial load in the joint.

We agree with the reviewer’s viewpoint that the increased infection burden in the tibiotarsal tissue of the infected SLPI-/- mice could contribute to the enhanced inflammation. A brief discussion of this possibility will be added to the revised manuscript.

(2) Fig. 1. (A) There is no statistically significant difference in the bacterial load in the heart or skin, in contrast to the tibiotarsal joint. It would be of interest to know whether other tissues that are routinely sampled to assess the bacterial load, such as injection site, knee, and bladder, also harbored increased bacterial load in SLPI-deficient mice. (B) Heart and joint burden were measured at "21-28" days. The two time points should be analyzed separately rather than pooled.

(A) We appreciate the reviewer’s suggestion. We agree that looking into the infection load in other tissues is helpful. However, studies into murine Lyme arthritis have been predominantly focused on tibiotarsal tissue, which displays the most consistent and prominent swelling that’s easy to observe and measure. Thus, we focused on the tibiotarsal joint in our study. (B) We collected the heart and joint tissue approximately 3-week post infection within a 3-day window based on the feasibility and logistics of the laboratory. Using “21-28 d”, we meant to describe between 21-24 days post infection. We apologize for the mislabeling and will correct it in the revised manuscript, stating approximately 3 weeks in the results, and defining approximately 3-weeks as between 21-24 days in the methods.

(3) Fig. 2. (A) The same ambiguity as to the days post-infection as cited above in Point 2B exists in this figure. (B) Panel B: Caliper measurements to assess joint swelling should be utilized rather than visual scoring. (In addition, the legend should make clear that the black circles represent mock-infected mice.)

(A) The histology scoring, and histopathology examination were performed at the same time as heart and joint tissue collection, approximately 3 weeks post infection within a 3-day window based on the feasibility and logistics of the laboratory. We apologize for the mislabeling and will correct it in the revised manuscript. (B) We appreciate the reviewer’s suggestion. However, our extensive experience is that caliper measurement can alter the assessment of swelling by placing pressure on the joints and did not produce consistent results. Double blinded scoring was thus performed. Histopathology examination was performed by an independent pathologist and confirmed the histology score and provided additional measurements.

(4) Fig. 3. (A) See Point 2B. (B) For Panels C-E, uninfected controls are lacking.

We apologize for this omission. Uninfected controls will be provided in the revised manuscript.

(5) Fig. 4. Fig. 4. Some LD subjects were sampled multiple times (5 samples from 3 subjects with Lyme arthritis; 13 samples from 4 subjects with EM), and samples from same individuals apparently are treated as biological replicates in the statistical analysis. In contrast, the 5 healthy controls were each sampled only once.

We agree with the reviewer that the control group is smaller than the patient group. Among the archived samples that are available, the number of adult healthy controls are limited, and sampled once. We used these samples to establish the baseline level of SLPI in the serum. It has been shown that the serum level of SLPI in healthy volunteers is in average about 40 ng/ml (DOI: 10.3389/fimmu.2019.00664 and 10.1097/00003246-200005000-00003). The median level in the healthy control in our data was 38.92 ng/ml, which is comparable to the previous results. A brief discussion will be added in the revised manuscript.

(6) Fig. 5. (A) Panel A: does binding occur when intact bacteria are used? (B) Panels B, C: Were bacteria probed with PI to indicate binding likely to occur to surface? How many biological replicates were performed for each panel? Is "antibody control" a no SLPI control? What is the blue line?

Actively growing B. burgdorferi were collected and used for binding assays. We do not permeabilize the bacteria for flow cytometry. Thus, all the binding detected occurs to the bacterial surface. Three biological replicates were performed for each panel. The antibody control is no SLPI control. For panel D, the bacteria were stained with Hoechst, which shows the morphology of bacteria. We apologize for the missing information. A complete and detailed description of Figure 5 will be provided in the revised manuscript.

(7) Sup Fig. 1. (A) Panel A: Was this experiment performed multiple times? I.e., how many biological replicates? (B) Panel B: Strain should be specified.

The binding assay to B. burgdorferi B31A was performed two times. In panel B, B. burgdorferi B31A3 was used. We apologize for the missing information. A complete and detailed description will be provided in the revised manuscript.

(8) Fig. S2. It is not clear that the condition (20% serum) has any bactericidal activity, so the potential protective activity of SLPI cannot be determined. (Typical serum killing assays in the absence of specific antibody utilized 40% serum.)

In Fig. S2, panel B, the first two bars (without SLPI, with 20% WT anti serum) showed around 40% viability. It indicates that the 20% WT anti serum has bactericidal activity. Serum was collected from B. burgdorferi-infected WT mice at 21 dpi, which should contain polyclonal antibody against B. burgdorferi.

Reviewer #3 (Recommendations for the authors):

It was a pleasure to review! I congratulate the authors on this elegant study. I think the manuscript is very well-written and clearly conveys the research outcomes. I only have minor suggestions to improve the readability of the text.

We greatly appreciate the reviewer’s recognition of our work.

Line 92: Please briefly summarize the key results of the study at the end of the introduction section.

We appreciate the reviewer’s suggestion. A brief summary will be added in the revised manuscript.

Line 108: Why is the inflammation significantly occurred only in ankle joints of SLPI-I mice? Could you please provide a brief explanation?

The inflammation may also happen in other joints the B. burgdorferi infected SLPI-/- mice, which has not been studied. The study into murine Lyme arthritis has been predominantly done in the tibiotarsal tissue, which displays the most prominent swelling that’s easy to observe and measure. Thus, we focused on the tibiotarsal joint in our study.

Line 136: Please also include the gene names in Figure 3.

We apologize for the omission. Gene names will be included in the revised manuscript.

Line 181: Please briefly introduce BASEHIT. Why did you use this tool? What are the benefits?

We appreciate the reviewer’s suggestion. We will provide more background information on BASEHIT in the revised manuscript.

  1. Howard Hughes Medical Institute
  2. Wellcome Trust
  3. Max-Planck-Gesellschaft
  4. Knut and Alice Wallenberg Foundation